Health Care · Biological Products, (No Diagnostic Substances)

TVGN Tevogen Bio Holdings Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 186087165 filings
Russell 2000

TVGN at a glance

Tevogen Bio Holdings Inc. (TVGN, SEC CIK 1860871) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of December 31, 2025, 18 institutional investment managers tracked by SignalX reported holding Tevogen Bio Holdings Inc. (TVGN) shares worth $1.2 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
18 funds
$1.2M · +3 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material risk-factor changes disclosed, with Item 1A containing no substantive risk-factor text
  • Liquidity risk: $144,713 cash versus $6,371,539 current liabilities at September 30, 2026
  • Financing risk: $1,651,000 notes payable remained in default following the Merger
  • Dilution risk: up to approximately 4.99 million additional shares issuable under the amended Loan Agreement
  • Clinical and regulatory risk: TVGN 489 and other candidates may fail development or required regulatory approval

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no products commercialized
  • Operating margin not applicable, operating loss $6.9M vs $5.7M YoY
  • Worst expense trend: G&A $3.9M vs $2.6M, driven by stock-based compensation
  • Cash $0.1M vs $0.6M at December 31, 2025, operating cash use $7.7M
  • Outlook: $28.6M borrowing availability and $7.0M committed grant, clinical trial deferred until manufacturing facility secured

AI summary of the TVGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Director Susan Podlogar resigned effective November 2, 2026
  • Board reduced from six to five directors, reducing governance capacity
Filed Nov 3, 2026Full analysis →

Item 3.02: Unregistered Sales of Equity Securities

  • Potential equity issuance to lender for debt repayment, creating dilution risk for TVGN shareholders
  • Pre-funded warrants may substitute for shares, preserving lender conversion economics while deferring share issuance

Item 1.01: Entry into a Material Definitive Agreement

  • Borrowing window extended to May 31, 2029, with post-amendment facility availability capped at $28.6 million
  • $7.4 million principal plus $177,880 accrued interest repaid through 1,023,733 shares at $7.40 per share

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO Ryan Saadi received 50,000,000 restricted shares, creating substantial potential dilution if the performance condition is achieved
  • Vesting requires $1.0 billion aggregate revenue by December 31, 2031, aligning compensation with a long-term growth target
Filed Sep 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Nasdaq Global Market compliance restored under the $50 million minimum market value requirement
  • Minimum market value of publicly held shares requirement also satisfied

Item 8.01: Other Events

  • Tevogen regained compliance with Nasdaq’s $50 million minimum market value requirement under Rule 5450(b)(2)(A)
  • Continued listing on The Nasdaq Global Market preserved, reducing delisting risk for TVGN and TVGNW holders

AI summaries of TVGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TVGN

Don't miss the next TVGN filing

  • Alerts as it files. A push when TVGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TVGN, by share count.
  • Ask anything. An AI agent that reads every TVGN filing and answers with sources.

TVGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Saadi Ryan H.ANov 2, 2026-
Desai KirtiASep 14, 2026-
Saadi Ryan H.ASep 14, 2026-
Goh Keow LinASep 11, 2026-
PODLOGAR SUSAN MASep 11, 2026-
Sordillo Victor J.ASep 11, 2026-
Patton Curtis L.ASep 11, 2026-
Feike Jeffrey L.ASep 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$8.8M-$53.6M-$26.1M
Net Income-$67K-$13.7M-$26.3M
Balance Sheet
Total Assets$17.0M$3.5M$4.4M
Equity-$17.4M-$6.7M-$8.2M
ROE0.4%205.7%319.1%
Per Share
EPS$-2.44$-0.07$-8.08
Cash Flow
Operating CF-$1.4M-$12.0M-$12.3M
CapEx$133K-$64K

Source: XBRL data in Tevogen Bio Holdings Inc. (TVGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q4 2025

Aggregate TVGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TVGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q4 202518$1.2M
Q3 202515$2.7M
Q2 202515$4.3M
Q1 202513$1.8M
Q4 20249$559,000
Position changes: Q3 2025 → Q4 2025
Top Buyers
Top Sellers
Closed Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 70 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TVGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 16, 2026Analysis
4Nov 4, 2026--
8-KNov 4, 2026Analysis-
8-KNov 3, 2026Analysis-
8-KSep 30, 2026Analysis-
4Sep 16, 2026--
4Sep 16, 2026--
8-KSep 16, 2026Analysis-
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
4Sep 15, 2026--
8-KSep 10, 2026Analysis-
8-KAug 26, 2026Analysis-
10-QAug 14, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
10-QMay 15, 2026Analysis

Related Health Care companies

All Health Care →

TVGN SEC filings: frequently asked questions

Which institutions hold TVGN stock?

As of December 31, 2025, the largest Tevogen Bio Holdings Inc. (TVGN) holders among the 13F filers tracked by SignalX were BlackRock ($395,000), Vanguard Group Inc ($376,000), Goldman Sachs Group ($91,000), Morgan Stanley ($83,000), Northern Trust ($65,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What did TVGN report in its latest 8-K?

Tevogen Bio Holdings Inc. (TVGN) filed an 8-K on November 4, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Director Susan Podlogar resigned effective November 2, 2026.

What are the latest TVGN SEC filings?

Tevogen Bio Holdings Inc. (TVGN) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 4, 2026.

What is TVGN's SEC CIK number?

Tevogen Bio Holdings Inc. (TVGN)'s SEC Central Index Key (CIK) is 1860871. EDGAR lists every TVGN filing under that number.

Ask anything about TVGN

The research agent reads TVGN's filings, financials, insider trades and 13F holders, then answers with sources.